Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Añadir filtros








Intervalo de año
2.
An. bras. dermatol ; 90(3,supl.1): 171-174, May-June 2015. tab, ilus
Artículo en Inglés | LILACS | ID: lil-755730

RESUMEN

Abstract

There are several studies on the benefits of using TNFα antagonists in the treatment of psoriasis, but few studies addressing the interaction of these drugs with chronic infections. We report the case of a 52-year-old patient diagnosed with psoriasis refractory to traditional systemic agents, who was treated with biologic therapies. After one year of treatment with biologic agents, the patient was diagnosed with Chagas Disease.

.


Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Adalimumab/uso terapéutico , Antiinflamatorios/uso terapéutico , Enfermedad de Chagas/tratamiento farmacológico , Psoriasis/tratamiento farmacológico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Factores Biológicos/uso terapéutico , Terapia Biológica/métodos , Reacción en Cadena de la Polimerasa , Reproducibilidad de los Resultados , Resultado del Tratamiento
3.
Indian J Dermatol Venereol Leprol ; 2012 Jul-Aug; 78(4): 448-453
Artículo en Inglés | IMSEAR | ID: sea-141130

RESUMEN

Background: Organ transplant recipients (OTR) are at high risk of developing cutaneous neoplasms. Topical photodynamic therapy (PDT) has been used for the treatment of actinic keratosis (AK) in OTR. Aims: The objective was to evaluate the efficacy of PDT with methylaminolevulinate (MAL) in the treatment of facial AK in OTR. As a secondary objective, we wanted to evaluate the usefulness of topical PDT in the reduction of photodamage in OTR. Methods: A prospective, single center, single arm study was made. 16 OTR were included. Topical PDT was applied for 1 or 2 cycles depending on the patient's characteristics. An evaluation of AK was made at visits pre-treatment, at 12 weeks and at 24 weeks. Photodamage was measured with multispectral image technique (SkinCare®). Results: A complete response rate of 100% was achieved for AK in all patients; it persisted without change at 12 and 24 weeks of follow-up. 62.5% of patients improved their photodamage as measured by SkinCare®, but this result was not statistically significant (P = 0.12). All patients had high level of satisfaction at the end of the therapy. Conclusions: MAL-PDT is an effective therapy for the treatment of AK in OTRs. It can reduce photodamage in this group of patients, but these results were not statistically significant.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA